Skip to contentC
Capricor Therapeutics, Inc.
C
CAPRCapricor Therapeutics, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$648.08K$648.08Kderived+36.2% vs Q4 2017 Net Income-$3.26M-$3.26MderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Capricor Therapeutics, Inc. · CIK 1133869 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,305,965N/M Operating Cash Flowderived-$3,771,215N/M Free Cash Flowderived-$3,755,620N/M Margins · derivedOperating margin-510.1%+179.3 pt vs Q4 2017
Net margin-503.0%
ended Dec 31, 2018 · filed Mar 29, 2019 · 88 d after period end